Hanwha Of S. Korea To Invest Heavy In Biotech Industry
This article was originally published in PharmAsia News
Executive Summary
South Korea's Hanwha Group is betting on the country's biotechnology industry as the next new area of growth. The conglomerate said its Hanwha Chemical and Dream Pharma units are set to collaborate for a major presence in the market for therapeutic antibodies. Hanwha's bio division has been working on the antibodies for the past two years and is ready to bring one of them to human clinical trials. Hanwha is investing just over $22 million in a large-scale production center. (Click here for more